摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

六甲烯亚氨基乙腈 | 54714-50-0

中文名称
六甲烯亚氨基乙腈
中文别名
——
英文名称
Hexamethylenimino-acetonitril
英文别名
Hexahydro-1H-azepine-1-acetonitrile;2-(azepan-1-yl)acetonitrile
六甲烯亚氨基乙腈化学式
CAS
54714-50-0
化学式
C8H14N2
mdl
MFCD00014115
分子量
138.213
InChiKey
OHKGIEVCPHMZKY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    110 °C (18 mmHg)
  • 密度:
    0.96
  • 稳定性/保质期:
    遵照规定使用和储存,则不会发生分解。

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.875
  • 拓扑面积:
    27
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 危险等级:
    6.1
  • 危险品标志:
    Xn
  • 安全说明:
    S24/25
  • 危险类别码:
    R20/21/22
  • 海关编码:
    2933990090
  • 危险品运输编号:
    UN 3276
  • 储存条件:
    存放于阴凉干燥处

SDS

SDS:2f5eb945e2c358af05b57cc46085db62
查看
Name: Hexahydro-1h-azepine-1-acetonitrile tech. ca.90% Material Safety Data Sheet
Synonym: (N-Hexamethyleneimino)acetonitrile; 1H-Azepine-1-acetonitrile, hexahydro-; Acetonitrile, (hexahydro-1H-azepin-1-yl)
CAS: 54714-50-0
Section 1 - Chemical Product MSDS Name:Hexahydro-1h-azepine-1-acetonitrile tech. ca.90% Material Safety Data Sheet
Synonym:(N-Hexamethyleneimino)acetonitrile; 1H-Azepine-1-acetonitrile, hexahydro-; Acetonitrile, (hexahydro-1H-azepin-1-yl)

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
54714-50-0 Hexahydro-1H-azepine-1-acetonitrile, t ca. 90 259-302-8
Hazard Symbols: XN
Risk Phrases: 20/21/22

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid immediately. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 54714-50-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Clear liquid
Color: clear, colorless
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 110 deg C @ 18.00mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: .9623g/cm3
Molecular Formula: C8H14N2
Molecular Weight: 138.21

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 54714-50-0: CM2500000 LD50/LC50:
Not available.
Carcinogenicity:
Hexahydro-1H-azepine-1-acetonitrile, tech. - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 54714-50-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 54714-50-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 54714-50-0 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Antihypertensively Active Amidoximes
    摘要:
    DOI:
    10.1021/ja01547a076
  • 作为产物:
    描述:
    环己亚胺 为溶剂, 反应 0.5h, 以92%的产率得到六甲烯亚氨基乙腈
    参考文献:
    名称:
    WO2006/104406
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • Fused heterocyclic compound and medicinal use thereof
    申请人:——
    公开号:US20040176361A1
    公开(公告)日:2004-09-09
    The fused heterocyclic compound of the present invention, which is represented by the formula (I): 1 wherein each symbol is as defined in the specification, an optically active form thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a water adduct thereof show poly(ADP-ribose) synthase inhibitory action and are useful as therapeutic drugs for cerebral infarction.
    本发明的融合杂环化合物,由式(I)表示:1其中每个符号如规范中所定义,其光学活性形式,其药学上可接受的盐,其水合物和水加合物均表现出聚(ADP-核糖)合酶抑制作用,并且可用作治疗脑梗塞的治疗药物。
  • Novel benzothiazepine and bensothiepine compounds
    申请人:Sasahara Takehiko
    公开号:US20070190041A1
    公开(公告)日:2007-08-16
    A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary biliary cirrhosis and primary sclerosing cholangitis, and a pharmaceutical useful as a therapeutic agent and a preventive agent for obesity, fatty liver and steatohepatitis are provided. A benzothiazepine or benzothiepine compound represented by the following formula (1A) having a thioamide bond and a quaternary ammonium substitutent:
    提供了一种药物,可用作治疗和预防高脂血症的治疗剂和预防剂,以及一种药物,可用作治疗和预防与胆汁淤积有关的肝脏疾病,特别是原发性胆汁性肝硬化和原发性硬化性胆管炎的治疗剂和预防剂,以及一种药物,可用作治疗和预防肥胖症、脂肪肝和脂肪性肝炎的治疗剂和预防剂。化合物的苯并噻吩或苯并噻环代表如下式(1A),具有硫酰胺键和季铵取代基:
  • Novel quaternary ammonium compounds
    申请人:Sasahara Takehiko
    公开号:US20070203115A1
    公开(公告)日:2007-08-30
    A method for inhibiting ileal bile acid transporter activity in a subject, comprising administering to said subject an effective amount of a compound represented by formula (1):
    一种抑制回肠胆汁酸转运蛋白活性的方法,包括向该受试者施用一种由式(1)所代表的化合物的有效量:
  • POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS COMTAINING A PROTECTED AMINO GROUP
    申请人:Luo Steven
    公开号:US20120059112A1
    公开(公告)日:2012-03-08
    A method for preparing a functionalized polymer, the method comprising the steps of (i) polymerizing monomer with a coordination catalyst to form a reactive polymer; and (ii) reacting the reactive polymer with a nitrile compound containing a protected amino group.
    一种制备功能化聚合物的方法,包括以下步骤:(i)使用配位催化剂聚合单体以形成反应性聚合物;(ii)将反应性聚合物与含有受保护氨基团的腈化合物反应。
  • Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments
    申请人:Auckland Uniservices Limited
    公开号:US07989451B2
    公开(公告)日:2011-08-02
    The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
    本发明涉及新型三环1,2,4-三嗪-1-氧化物和新型三环1,2,4-三嗪-1,4-二氧化物的公式I以及相关类似物,涉及它们的制备,以及它们作为缺氧选择性药物和放射增敏剂用于癌症治疗,无论是单独使用还是与放射治疗和/或其他抗癌药物联合使用。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

黄莲素 铜(2+)9,23-二(丁基氨磺酰)-2,16-二[(2-乙基己基)氨磺酰]酞菁-29,31-二负离子 西替地尔 苯甲酯庚 美索庚嗪 美普他酚 缩氨基硫脲H 禾草敌-亚砜 禾草敌 碘正离子,(4-丁基苯基)-1-戊炔-1-基- 盐酸美普他酚 甲基3-(2-硫代-1-氮杂环庚基)丙酸酯 环己亚胺 氮杂环庚烷-4-羧酸乙酯 氮杂环庚烷-3-酮盐酸盐 氮杂环庚烷-3-羧酸乙酯盐酸盐 氮杂环庚烷-3-基甲醇盐酸盐 氮杂环庚烷-3-基-甲基-胺 氮杂环庚烷-1-二硫代甲酸 氮杂环庚-4-酮 氮杂烷-1,3-二羧酸 1-叔丁酯 氮杂-1-基(环戊基)乙腈 氨基甲酸,N-(六氢-1H-氮杂环庚烯-3-基)-,1,1-二甲基乙基酯 氨基甲二硫酸,(六氢-1H-吖庚英-1-基)-,1-乙酰基-2-羰基丙基酯 吖庚环-1-基(苯基)乙酰腈 叔-丁基4-氨基-5-甲基吖庚环-1-甲酸基酯 叔-丁基4-亚甲基氮杂环庚烷-1-羧酸酯 叔-丁基1-(羟甲基)-6-氮杂螺[2.6]壬烷-6-甲酸基酯 双六亚甲基脲 十氢吡嗪并[1,2-a]氮杂卓 六甲烯亚氨基乙腈 六甲烯二硫代]氨基甲酸 六甲基铵盐 六氢化-1H-4-氮杂卓胺 六氢-alpha-甲基-1H-氮杂卓-1-丙酸甲酯盐酸盐(1:1) 六氢-alpha-甲基-1H-氮杂卓-1-丙酸甲酯 六氢-4-(羟基甲基)-1,1-二甲基-4-苯基-1H-氮杂卓鎓溴化物(1:1) 六氢-3,3,5-三甲基-1H-氮杂ze盐酸盐 六氢-2-甲基-1H-氮杂卓盐酸盐 六氢-2-[(3-甲基-4-吡啶)甲基]-1H-氮杂卓 六氢-1H-氮杂卓-4-醇盐酸盐 六氢-1H-氮杂卓-4-醇 六氢-1H-氮杂卓-4-羧酸甲酯 六氢-1H-氮杂卓-1-羧酸乙酯 六氢-1H-氮杂卓-1-硫代羧酸 六氢-1H-氮杂卓-1-甲醛 六氢-1H-氮杂卓-1-甲酰氯 六氢-1H-氮杂-1-丙酸乙酯 六氢-1-月桂酰-1H-氮杂卓 六氢-1-(甲氧基亚甲基)-1H-氮杂卓鎓硫酸甲酯盐 六氢-1-(2-Th烯亚基氨基)-1H-氮杂卓